Day One Biopharmaceuticals, Inc. (DAWN)

Compare

7.61

-0.32

(-4.04%)

At close: April 1 at 4:00:01 PM EDT

High Growth Tech Stocks In The US With Promising Potential

Over the last 7 days, the United States market has experienced a 1.7% drop, yet it remains up by 12% over the past year with earnings forecasted to grow by 14% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability in an evolving market landscape.

Simply Wall St. 22 days ago

ARDX

DAWN
-4.04%
BSY
Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case Theory

We came across a bullish thesis on Day One Biopharmaceuticals, Inc. (DAWN) on Twitter by Pharmdca. In this article, we will summarize the bulls’ thesis on DAWN. Day One Biopharmaceuticals, Inc. (DAWN)’s share was trading at $8.60 as of March 4th. DAWN is an undervalued commercial-stage oncology company with a long-term target in the mid-$30s, driven by […]

Insider Monkey 27 days ago

DAWN
-4.04%
Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations

Jazz reports better-than-expected fourth-quarter results. Its newly issued EPS guidance of $22.50-$24.00 for full-year 2025 surpasses our expectations.

Zacks last month

DAWN
-4.04%
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates

Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of -97.14% and 7.74%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

DAWN
-4.04%
Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively Ended 2024 with $531.7 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, February 25, 4:30 p.m. ET BRISBANE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted

GlobeNewswire last month

DAWN
-4.04%
Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates

INSM posts wider-than-expected Q4 loss. It reiterates its 2025 sales outlook for Arikayce in the range of $405-$425 million.

Zacks last month

INSM

DAWN
-4.04%
Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect?

The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 193.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks last month

DAWN
-4.04%
New Strong Buy Stocks for February 13th

SYF, SSB, VCYT, DAWN and FISI have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2025.

Zacks last month

SYF-PB

DAWN
-4.04%
Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025

BRISBANE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 25, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the fourth quarter and full-year 2024. Live audio of the

GlobeNewswire last month

DAWN
-4.04%
Why Is Andreas Halvorsen Bullish On Day One Biopharmaceuticals, Inc. (DAWN) Now?

We recently compiled a list of the Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks. In this article, we are going to take a look at where Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) stands against Andreas Halvorsen’s other long-term stock picks. Andreas Halvorsen is a prominent Norwegian hedge fund manager and the co-founder of Viking Global, one […]

Insider Monkey 2 months ago

DAWN
-4.04%
New Tariffs Didn’t Come on Trump’s Day One. A Trade War May Not Be in the Wings.

The likelihood of an all-out trade war may have receded but not the trade-related volatility as stocks climbed.

Barrons.com 2 months ago

DAWN
-4.04%
President Trump outlines a frenzy of Day One executive orders and actions: Here’s a list of what to expect

The agenda includes actions on immigration, the military, gender identity, the economy, and renaming the Gulf of Mexico.

FastCompany 2 months ago

DAWN
-4.04%
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities

Preliminary 2024 OJEMDA™ (tovorafenib) net product revenue of approximately $57.2 million (unaudited) First dose cohort cleared in Phase 1a/b clinical trial of DAY301 (PTK7-targeted ADC) Ended 2024 with approximately $531.7 million in cash, cash equivalents and short-term investments (unaudited) Company to present at 43rd Annual J.P. Morgan Healthcare Conference today at 3:45 p.m. Pacific Time (6:45 p.m. Eastern Time) BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals

GlobeNewswire 2 months ago

DAWN
-4.04%
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025

Here we present three biotech stocks, ALLO, DAWN and IMCR, which took a beating in 2024 but have upside potential for 2025.

Zacks 3 months ago

DAWN
-4.04%
ALLO
Are These AI Stocks Ready for a Comeback?

Editor’s Note: My InvestorPlace colleague Luke Lango has been covering the two waves of the AI Revolution – the AI Builders and the AI Appliers – for the past few years. And readers of his research benefited tremendously after he spotted the AI Applier wave before it actually arrived. For example, Luke recommended top AI Applier stocks like Axon Enterprise Inc. (AXON) and AppLovin Corp. (APP) — now both up 350%-plus — before the crowd caught on. It’s why my other InvestorPlace colleague Eric Fry

InvestorPlace 3 months ago

DAWN
-4.04%
APP
High Growth Tech Stocks to Watch in December 2024

Over the last 7 days, the United States market has dropped by 2.7%, yet it has risen by an impressive 23% over the past year, with earnings forecasted to grow by 15% annually. In this context of robust annual growth despite recent fluctuations, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in a dynamic market environment.

Simply Wall St. 3 months ago

WBTN

DAWN
-4.04%
HUMA
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13 at 3:45 p.m. Pacific Time / 6:45 p.m. Eastern Time. A live audio webcast

GlobeNewswire 3 months ago

DAWN
-4.04%
How Trump Can Help Crypto on Day One

A simple executive order issued on Jan. 20 would pave the way for the crypto sector’s resurgence in the U.S.

CoinDesk 3 months ago

DAWN
-4.04%
Instagram locks out developers of third-party consumer apps

A change to Meta's developer tools is impacting third-party consumer apps that had previously integrated with Instagram. Among those affected by the changes are the Match-owned dating apps Tinder and Hinge, which had allowed their users to link their Instagram profiles to their accounts to display their posts to potential matches. Day One, the journaling app that WordPress.com owner Automattic bought in 2021, is also losing a key piece of its functionality because of the change. The company anno

TechCrunch 3 months ago

DAWN
-4.04%
Why Is Day One Biopharmaceuticals Inc. (DAWN) Among the Best Up and Coming Stocks to Buy According to Analysts?

We recently compiled a list of the 10 Best Up and Coming Stocks To Buy According to Analysts. In this article, we are going to take a look at where Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) stands against the other up and coming stocks. Donald Trump’s victory in the recent presidential election is expected to encourage companies […]

Insider Monkey 4 months ago

DAWN
-4.04%

Performance Overview

Return	DAWN	S&P 500 (^GSPC)
YTD	-39.94%	-4.23%
1-Year	-52.91%	+7.42%
3-Year	-27.94%	+23.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Day One Biopharmaceuticals, Inc. (DAWN)

High Growth Tech Stocks In The US With Promising Potential

Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case Theory

Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations

Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates

Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates

Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect?

New Strong Buy Stocks for February 13th

Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025

Why Is Andreas Halvorsen Bullish On Day One Biopharmaceuticals, Inc. (DAWN) Now?

New Tariffs Didn’t Come on Trump’s Day One. A Trade War May Not Be in the Wings.

President Trump outlines a frenzy of Day One executive orders and actions: Here’s a list of what to expect

Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities

3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025

Are These AI Stocks Ready for a Comeback?

High Growth Tech Stocks to Watch in December 2024

Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference

How Trump Can Help Crypto on Day One

Instagram locks out developers of third-party consumer apps

Why Is Day One Biopharmaceuticals Inc. (DAWN) Among the Best Up and Coming Stocks to Buy According to Analysts?

Performance Overview